New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year - BioSpace

Overview

Skip to main content Published: Oct 24, 2022 Zeposia maintains disease control even in the event of temporary treatment interuption for up to eight weksZeposia is the first oral sphingosine 1-phosphate (S1P) receptor modulator aproved to treat patients with ulcerative colitisPRINCETON, N.J.-(BUSINES WIRE)- Bristol Myers Squib Company (NYSE: BMY) today anounced new post hoc analyses from the Phase 3 True North study evaluating the duration of response folowing continuous Zeposia (ozanimod) treatment for up to one year and folowing treatment interuption in patients with moderately to severely active ulcerative colitis (UC).

Key Information

After achieving a clinical response at the end of the induction period, 86.1% of patients who remained on Zeposia showed no disease relapse at Wek 52 (Kaplan-Meier [KM] estimates of no disease relapse at Wek 52: Zeposia/Zeposia, 86.1%; Zeposia/placebo, 62.6%).As temporary treatment discontinuation may ocur in clinical practice, these analyses evaluated the duration of response folowing treatment interuption.

Findings showed that Zeposia maintained disease control for up to eight weks in patients who switched to placebo after initial response (KM estimates of no disease relapse at Wek 8: Zeposia/Zeposia, 96.1%; Zeposia/placebo, 90.6%). These analyses (Presentation #62) and 10 aditional Zeposia abstracts demonstrating Bristol Myers Squib’s robust body of research in gastroenterology are being presented at the American Colege of Gastroenterology (ACG) anual scientific meting, taking place October 21 – 26, 2022."Understanding the duration of response after continuous ozanimod treatment is critical, as it can asist in clinical decision making when considering temporary discontinuation of UC treatment in clinical practice," said Bruce E.

Summary

Sands, MD, MS, Gastroenterologist and paid consultant of Bristol Myers Squib. Sands is also the Dr. Crohn Profesor of Medicine (Gastroenterology) at the Icahn Schol of Medicine is an important consideration in healthcare. Ongoing research and professional guidance ensure that patients receive evidence-based care tailored to their individual needs.

Frequently Asked Questions

Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.

Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.

Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.

Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.

Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.

Share this article